ACOR - Acorda Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
18.55
-0.20 (-1.07%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close18.75
Open18.75
Bid0.00 x 1100
Ask0.00 x 2900
Day's Range18.50 - 19.10
52 Week Range15.60 - 36.35
Volume454,956
Avg. Volume652,882
Market Cap880.824M
Beta2.40
PE Ratio (TTM)N/A
EPS (TTM)-3.42
Earnings DateOct 29, 2018 - Nov 2, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est23.22
Trade prices are not sourced from all markets
  • See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.
    Markit6 days ago

    See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.

    Acorda Therapeutics Inc NASDAQ/NGS:ACOR

  • See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.
    Markit9 days ago

    See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.

    Acorda Therapeutics Inc NASDAQ/NGS:ACOR

  • Acorda (ACOR) Stock Dips, FDA Delays Decision on Inbrija
    Zacks12 days ago

    Acorda (ACOR) Stock Dips, FDA Delays Decision on Inbrija

    The FDA defers decision by three months regarding the NDA of Acorda's (ACOR) Parkinson's disease candidate Inbrija for the treatment of OFF periods.

  • Associated Press12 days ago

    Qualcomm and Tailored Brands rise; Kroger stumbles

    Stocks that moved substantially or traded heavily Thursday: Progenics Pharmaceuticals Inc., down $1.30 to $6 The company reported disappointing results from a study of an imaging compound used in prostate ...

  • Motley Fool13 days ago

    Here's Why Acorda Therapeutics Is Falling by Double Digits Today

    Shares retreated after the company provided Wall Street with an updated regulatory timeline. Here's what investors need to know.

  • MarketWatch13 days ago

    Acorda shares slide 19% premarket after FDA delays review of Parkinson's treatment

    Shares of Acorda Therapeutics Inc. slid 19% Thursday, after the company said the U.S. Food and Drugs Administration has extended the review period for a treatment for symptoms of Parkinson Disease. The extension comes after Acorda submitted additional information on its Inbrija, an inhaled levodopa therapy that aims to reduce off times, or the periods when standard levodopa treatment stops working. The FDA determined that the additional information constituted a major amendment that would take longer to review. The regulator moved the review date back to Jan. 5, 2019 from Oct. 5, 2018. Parkinson's is a progressive neurodegenerative disorder that affects about 1 million people in the U.S. and 1.2 million people in Europe. Acorda shares have fallen 13.8% in 2018, while the S&P 500 has gained 8.1%.

  • Business Wire13 days ago

    Acorda Announces FDA Extends INBRIJA NDA Review Period

    Acorda Therapeutics, Inc. (ACOR) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its review of the New Drug Application (NDA) of INBRIJA™ (levodopa inhalation powder) from October 5, 2018 to January 5, 2019. This extension is related to recent submissions Acorda made in response to requests from FDA for additional information on chemistry, manufacturing and controls (CMC). FDA determined that these submissions constitute a major amendment and will take additional time to review.

  • Acorda Gets Unfavorable Court Ruling for Ampyra, Stock Down
    Zacks15 days ago

    Acorda Gets Unfavorable Court Ruling for Ampyra, Stock Down

    Acorda Therapeutics' (ACOR) stock slumps after a Federal Circuit Court rules against its appeal to protect patents pertaining to its key multiple sclerosis drug, Ampyra

  • Are Options Traders Betting on a Big Move in Acorda (ACOR) Stock?
    Zacks15 days ago

    Are Options Traders Betting on a Big Move in Acorda (ACOR) Stock?

    Investors need to pay close attention to Acorda (ACOR) stock based on the movements in the options market lately.

  • ACCESSWIRE15 days ago

    Today’s Research Reports on Stocks to Watch: Acorda Therapeutics and Avid Bioservices

    NEW YORK, NY / ACCESSWIRE / September 11, 2018 / Acorda shares were deep in the red after a disappointing court ruling on Monday. A U.S. District Court of Appeals has held up a lower court ruling invalidating key patents on Ampyra, the company’s multiple sclerosis drug that accounts for most of its sales. Shares of Avid Bioservices traded fairly flat during the day but soared in after-hours extended trading after reporting stellar first quarter financial results.

  • Why Brown-Forman, Acorda Therapeutics, and Energy XXI Gulf Coast Slumped Today
    Motley Fool15 days ago

    Why Brown-Forman, Acorda Therapeutics, and Energy XXI Gulf Coast Slumped Today

    Find out which of these companies lost the most ground.

  • What's Behind Acorda Therapeutics Crashing 24.5% Today
    Motley Fool15 days ago

    What's Behind Acorda Therapeutics Crashing 24.5% Today

    The company could face stiff competition following an unfavorable ruling by an appeals court.

  • MarketWatch16 days ago

    Acorda's stock plunges after disappointing ruling regarding patents for MS treatment

    Shares of Acorda Therapeutics Inc. plunged 21% toward an 8-month low in midday trade Monday, after a disappointing ruling a federal appeals court on patents pertaining to its multiple sclerosis treatment, Ampyra. The company said the U.S. Court of Appeals upheld by a 2-to-1 vote the U.S. District Court of Delaware's decision to invalidate four Ampyra patents. That validates the District Court's ruling on March 31, 2017, which invalidated patents pertaining to Ampyra extended release tablets. Acorda said it was reviewing the decision and its options, including a further appeal. "We are disappointed by the Court's decision, as we continue to believe that our AMPYRA patents reflected true invention and were valid," Chief Executive Ron Cohen said in a statement. "Following the Court's original decision in 2017, we prepared a contingency plan that we could face generic competition, implementing a comprehensive corporate restructuring and bolstering our balance sheet." Despite the stock's sharp selloff, it has gained 1.2% year to date, while the S&P 500 has tacked on 7.7%.

  • Business Wire16 days ago

    U.S. Court of Appeals for the Federal Circuit Upholds District Court’s Decision to Invalidate AMPYRA® (dalfampridine) Patents

    Acorda Therapeutics, Inc. (ACOR) today announced that the United States Court of Appeals for the Federal Circuit, by a 2-1 vote, has upheld the United States District Court for the District of Delaware’s decision to invalidate four AMPYRA patents. This decision affirms the District Court’s ruling on March 31, 2017 invalidating U.S. Patent Nos. 8,663,685 (the ‘685 patent), 8,007,826 (the ‘826 patent), 8,440,703 (the ‘703 patent), and 8,354,437 (the ‘437 patent) pertaining to AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg. Acorda’s U.S. Patent No. 5,540,938 (the ‘938 patent), previously upheld by the District Court, expired on July 30, 2018.

  • See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.

    Acorda Therapeutics Inc NASDAQ/NGS:ACOR

  • GlobeNewswirelast month

    Market Trends Toward New Normal in Acorda Therapeutics, Red Robin Gourmet Burgers, Plug Power, Group 1 Automotive, Shutterfly, and National Fuel Gas — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Aug. 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Acorda ...

  • Business Wirelast month

    Acorda Announces Management Transitions

    Acorda Therapeutics, Inc. (ACOR) today announced that Rick Batycky, Ph.D., Chief Technology Officer, will be leaving Acorda as of August 20, 2018 to take a position as the CEO of a private, venture-backed biotechnology company. David Lawrence, Acorda’s Chief of Business Operations, will assume responsibility for the company’s Chelsea, MA manufacturing facility, which produces INBRIJA™ (levodopa inhalation powder), as well as for the external manufacturing of AMPYRA® (dalfampridine). Burkhard Blank, M.D., Acorda’s Chief Medical Officer, will assume responsibility for Acorda’s Pharmaceutical Development and Technical Operations teams.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of ACOR earnings conference call or presentation 2-Aug-18 12:30pm GMT

    Q2 2018 Acorda Therapeutics Inc Earnings Call

  • See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.

    Acorda Therapeutics Inc NASDAQ/NGS:ACOR

  • Acorda (ACOR) Q2 Earnings and Revenues Surpass Estimates
    Zacks2 months ago

    Acorda (ACOR) Q2 Earnings and Revenues Surpass Estimates

    Acorda Therapeutics (ACOR) rides high on earnings as well as revenue beat in Q2.

  • Is the Options Market Predicting a Spike in Acorda Therapeutics (ACOR) Stock?
    Zacks2 months ago

    Is the Options Market Predicting a Spike in Acorda Therapeutics (ACOR) Stock?

    Investors need to pay close attention to Acorda Therapeutics (ACOR) stock based on the movements in the options market lately.

  • Acorda Therapeutics (ACOR) Q2 Earnings and Revenues Beat Estimates
    Zacks2 months ago

    Acorda Therapeutics (ACOR) Q2 Earnings and Revenues Beat Estimates

    Acorda (ACOR) delivered earnings and revenue surprises of 86.67% and 19.10%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • ACCESSWIRE2 months ago

    Acorda Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 2, 2018 / Acorda Therapeutics, Inc. (NASDAQ: ACOR ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 2, 2018 at 8:30 AM Eastern ...

  • Associated Press2 months ago

    Acorda: 2Q Earnings Snapshot

    The Ardsley, New York-based company said it had net income of 98 cents per share. Earnings, adjusted for one-time gains and costs, came to $1.40 per share. The results exceeded Wall Street expectations. ...

  • Business Wire2 months ago

    Acorda Provides Financial and Pipeline Update for Second Quarter 2018

    ARDSLEY, N.Y.-- -- INBRIJA™ NDA under FDA review; PDUFA date October 5, 2018 AMPYRA® 2Q 2018 net sales of $150.3 million; reiterating 2018 guidance of $330-$350 million Awaiting AMPYRA patent decision from U.S. Court of Appeals Acorda Therapeutics, Inc. provided a financial and pipeline update for the quarter ended June 30, 2018. “Our outstanding quarter reflected the continued excellence of our specialty ...